Vernalis PLC Regulatory News (VER)

20 Dec 2006 09:50

Vernalis PLC20 December 2006 20 December 2006 Vernalis Plc Strengthens Commercial Expertise by new Appointment to the Board - Ian Clark from Genentech - WINNERSH, U.K., December 20, 2006 -- Vernalis plc (LSE: VER, Nasdaq: VNLS) todayannounces the appointment of Ian Clark as a Non-Executive Director with effectfrom 1st January 2007. He currently serves as Executive Vice President,Commercial at Genentech, and he is responsible for leading their commercialorganisation, including the Sales, Marketing, Managed Care, Market Development,and Commercial Operations functions. Before joining Genentech in 2004, he served as president of Novartis Canada,overseeing all of the company's country operations. Before assuming his post inCanada, he served as Chief Operating Officer for Novartis in the UK. Prior tojoining Novartis in 1999, Ian worked in Vice Presidential roles in sales andmarketing for Sanofi (Aventis) and Ivax in the UK and Eastern Europe. Hereceived a Bachelor of Science degree in Biological Sciences from SouthamptonUniversity. Peter Fellner, Chairman of Vernalis commented: "We are delighted that Ian has agreed to join our Board. His exceptional salesand marketing knowledge will help Vernalis as it continues to develop itscommercial expertise. Establishing our U.S. business is an important part ofVernalis' growth strategy. With two products on the market and a strong productportfolio in development, his commercial experience will be invaluable toVernalis." Ian Clark commenting on his appointment said: "Vernalis is at an exciting stage of its development. The Company's commercialorganisation is already marketing its own products and I look forward to lendingmy experience and perspective to the management team as they grow current salesand prepare for future product launches." -- ends -- Enquiries:Vernalis plc +44 (0) 118 977 3133Simon Sturge, Chief Executive OfficerTony Weir, Chief Financial OfficerJulia Wilson, Head of Corporate Communications Brunswick Group +44 (0) 20 7404 5959Jon ColesJustine McIlroy Lazar Partners LtdGregory Gin 212-867-1762 Notes to Editors About Vernalis Vernalis is a speciality bio-pharmaceutical company focused on products marketedto specialist neurologists. The company has two marketed products, Frova(R) andApokyn(R), and a development pipeline focused on neurology and central nervoussystem disorders. The company has eight products in clinical development andcollaborations with leading, global pharmaceutical companies including Novartis,Biogen Idec and Serono. Vernalis has established a US commercial operation topromote Apokyn(R) and co-promote Frova(R) alongside its North American licensingpartner, Endo Pharmaceuticals, progressing the company towards its goal ofbecoming a sustainable, self-funding, R&D-driven, speciality bio-pharmaceuticalcompany. For further information about Vernalis, please visit: www.vernalis.com +-------+-----------+-----+-----+-----+------------+------+------------+|Product|Indication |Phase|Phase|Phase| | |Marketing || | | I | II | III |Registration|Market| Rights || | | | | | | | |+-------+-----------+-----+-----+-----+------------+------+------------+|Apokyn |Parkinson's| | | | | x |North ||(R) |Disease | | | | | |America || | | | | | | | |+-------+-----------+-----+-----+-----+------------+------+------------+|Frova |Migraine | | | | | x |US ||(R) | | | | | | |milestones &|| | | | | | | |royalties - || | | | | | | |Endo || | | | | | | |(EU - || | | | | | | |royalties) |+-------+-----------+-----+-----+-----+------------+------+------------+|Frova |Menstrual | | | | x | |US ||(R) |Migraine | | | | | |milestones &|| |Prevention | | | | | |royalties - || | | | | | | |Endo || | | | | | | |(EU - || | | | | | | |royalties) |+-------+-----------+-----+-----+-----+------------+------+------------+|V1512 |Parkinson's| | x | | | |World Wide || |Disease | | | | | |(excl. || | | | | | | |Italy) |+-------+-----------+-----+-----+-----+------------+------+------------+|V10153 |Ischaemic | | x | | | |World Wide || |stroke | | | | | | |+-------+-----------+-----+-----+-----+------------+------+------------+|V1003 |Acute Pain | | x | | | |US Profit || | | | | | | |share Option|| | | | | | | |Reckitt || | | | | | | |Benckiser |+-------+-----------+-----+-----+-----+------------+------+------------+|V3381 |Neuropathic| | x | | | |World Wide || |Pain | | | | | | |+-------+-----------+-----+-----+-----+------------+------+------------+|V2006 |Parkinson's| x | | | | |US || |Disease | | | | | |Co-promotion|| | | | | | | |Biogen Idec |+-------+-----------+-----+-----+-----+------------+------+------------+|MMPI |Multiple | x | | | | |None - || |Sclerosis | | | | | |royalty || | | | | | | |(Serono) |+-------+-----------+-----+-----+-----+------------+------+------------+|V24343 |Obesity | x | | | | |World Wide |+-------+-----------+-----+-----+-----+------------+------+------------+ Vernalis Forward-Looking Statement This news release may contain forward-looking statements that reflect theCompany's current expectations regarding future events including the clinicaldevelopment and regulatory clearance of the Company's products, the Company'sability to find partners for the development and commercialisation of itsproducts, as well as the Company's future capital raising activities.Forward-looking statements involve risks and uncertainties. Actual events coulddiffer materially from those projected herein and depend on a number of factorsincluding the success of the Company's research strategies, the applicability ofthe discoveries made therein, the successful and timely completion of clinicalstudies, the uncertainties related to the regulatory process, the ability of theCompany to identify and agree beneficial terms with suitable partners for thecommercialisation and/or development of its products, as well as the achievementof expected synergies from such transactions, the acceptance of Frova(R) andApokyn(R) and other products by consumers and medical professionals, thesuccessful integration of completed mergers and acquisitions and achievement ofexpected synergies from such transactions, and the ability of the Company toidentify and consummate suitable strategic and business combinationtransactions. This information is provided by RNS The company news service from the London Stock Exchange